InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 42.82
+2.98 (7.48%)
Jul 10, 2026, 4:08 PM HKT
HKG:3696 Revenue
In the year 2025, InSilico Medicine Cayman TopCo had annual revenue of $56.24M USD, down -34.48%. InSilico Medicine Cayman TopCo had revenue of $28.78M in the half year ending December 31, 2025.
Revenue
$56.24M
Revenue Growth
-34.48%
P/S Ratio
52.10
Revenue / Employee
$177.41K
Employees
317
Market Cap
22.80B HKD
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.24M | -29.60M | -34.48% |
| Dec 31, 2024 | 85.83M | 34.65M | 67.71% |
| Dec 31, 2023 | 51.18M | 21.03M | 69.77% |
| Dec 31, 2022 | 30.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionInSilico Medicine Cayman TopCo News
- 1 day ago - Insilico Medicine Releases Positive Profit Alert for the First Half of 2026 - PRNewsWire
- 8 days ago - Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery - PRNewsWire
- 8 days ago - Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million - WSJ
- 14 days ago - InSilico Is on a Mission: Be No. 1 in China, Create ‘God Drug' With AI - WSJ
- 18 days ago - Insilico Medicine And SK Biopharma Ink AI-Driven CNS Drug Discovery Partnership; Stock Up - Nasdaq
- 5 weeks ago - InSilico Medicine Cayman TopCo Earnings Call Transcript: Q4 2025 - Transcripts
- 5 weeks ago - InSilico Medicine Cayman TopCo Earnings release: Q4 2025 - Filings
- 2 months ago - InSilico Medicine Cayman TopCo Slides: Corporate presentation - Filings